Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: SciClone Pharmaceuticals Clear all
Completed No phase listed Observational

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

NCT01310205
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Louisville, Kentucky • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 3, 2026, 1:01 PM EDT
Completed Phase 2 Interventional

Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

NCT00756951
View directory record Official record
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
Placebo, SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 3, 2026, 1:01 PM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00039962
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 3, 2026, 1:01 PM EDT
Completed Phase 2 Interventional

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

NCT00082082
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Thymalfasin (thymosin alpha-1), Trans arterial chemoembolization (TACE)
Drug · Procedure
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Gainesville, Florida • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 3, 2026, 1:01 PM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

NCT00968357
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SCV-07
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 3, 2026, 1:01 PM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 3, 2026, 1:01 PM EDT
Terminated Phase 2 Interventional

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

NCT00550004
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RP101, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 3, 2026, 1:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

NCT05566041
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 3, 2026, 1:01 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

NCT01247246
View directory record Official record
Conditions
Oral Mucositis
Interventions
SCV-07, Placebo
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
49
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 3, 2026, 1:01 PM EDT